Literature DB >> 29050566

How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD.

Kimberly N Hong1, Valentin Fuster1, Robert S Rosenson1, Clive Rosendorff1, Deepak L Bhatt2.   

Abstract

Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict cardiovascular disease events. The effect of these risk factors on incident cardiovascular disease increases with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure. The thresholds for initiating treatment of these modifiable risk factors and the optimal goals of risk factor modification are a focus of primary prevention research. Although an aggressive approach is appealing, adverse events may occur, and potential physiological barriers may exist. This paper discusses primary prevention of coronary heart disease that may be achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current guidelines and pertinent clinical trial data from intervention trials that included a primary prevention cohort.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; diabetes; hyperlipidemia; hypertension; primary prevention

Mesh:

Substances:

Year:  2017        PMID: 29050566     DOI: 10.1016/j.jacc.2017.09.001

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

Review 1.  Prevention of Diabetes Mellitus in Patients With Prediabetes.

Authors:  Nicholas W Carris; Ronald R Magness; Arthur J Labovitz
Journal:  Am J Cardiol       Date:  2018-11-06       Impact factor: 2.778

Review 2.  Beyond Statins: Who and When to Prescribe?

Authors:  Om Ganda
Journal:  Curr Diab Rep       Date:  2018-10-15       Impact factor: 4.810

3.  Sexual minorities are at elevated risk of cardiovascular disease from a younger age than heterosexuals.

Authors:  Jessica Sherman; Christina Dyar; Jodi McDaniel; Nicholas T Funderburg; Karen M Rose; Matt Gorr; Ethan Morgan
Journal:  J Behav Med       Date:  2022-01-16

4.  Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial.

Authors:  Gaoxing Zhang; Yongqiang Fan; Yumin Qiu; Zhe Zhou; Jianning Zhang; Zhichao Wang; Yuanya Liu; Xing Liu; Jun Tao
Journal:  Adv Ther       Date:  2020-06-24       Impact factor: 3.845

5.  Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?

Authors:  Kathleen A Fairman; Lindsay E Davis; Alyssa M Peckham; David A Sclar
Journal:  Drugs Real World Outcomes       Date:  2018-03

Review 6.  Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.

Authors:  William E Boden; Deepak L Bhatt; Peter P Toth; Kausik K Ray; M John Chapman; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2020-06-21       Impact factor: 29.983

7.  Blood pressure control of hypertensive patients followed in a high complexity clinic and associated variables.

Authors:  Juliana Chaves Coelho; Mayra Cristina da Luz Pádua Guimarães; Cassia Lima de Campos; Carime Farah Florido; Giovanio Vieira da Silva; Angela Maria Geraldo Pierin
Journal:  J Bras Nefrol       Date:  2021 Apr-Jun

8.  A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.

Authors:  Woo Youl Kang; Hae Won Lee; Mi-Ri Gwon; Seungil Cho; Wang-Seob Shim; Kyung-Tae Lee; Dong Heon Yang; Sook Jin Seong; Young-Ran Yoon
Journal:  Drug Des Devel Ther       Date:  2020-05-26       Impact factor: 4.162

9.  Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings.

Authors:  Mohamed Hassan Elnaem; Mohamad Haniki Nik Mohamed; Hasniza Zaman Huri; Azarisman Shah Mohd Shah
Journal:  Ther Clin Risk Manag       Date:  2019-01-18       Impact factor: 2.423

Review 10.  Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series.

Authors:  Peter E H Schwarz; Patrick Timpel; Lorenz Harst; Colin J Greaves; Mohammed K Ali; Jeffrey Lambert; Mary Beth Weber; Mohamad M Almedawar; Henning Morawietz
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.